A detailed history of Virtus Fund Advisers, LLC transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Virtus Fund Advisers, LLC holds 163 shares of BPMC stock, worth $18,740. This represents 0.05% of its overall portfolio holdings.

Number of Shares
163
Previous 303 46.2%
Holding current value
$18,740
Previous $27,000 44.44%
% of portfolio
0.05%
Previous 0.17%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$73.17 - $99.79 $10,243 - $13,970
-140 Reduced 46.2%
163 $15,000
Q4 2023

Feb 15, 2024

SELL
$43.96 - $92.84 $9,451 - $19,960
-215 Reduced 41.51%
303 $27,000
Q4 2022

Feb 14, 2023

BUY
$41.06 - $66.48 $21,269 - $34,436
518 New
518 $22,000
Q3 2022

Nov 14, 2022

SELL
$49.93 - $77.7 $230,227 - $358,274
-4,611 Closed
0 $0
Q4 2017

Feb 09, 2018

BUY
$62.91 - $88.32 $290,078 - $407,243
4,611
4,611 $348,000

Others Institutions Holding BPMC

About Blueprint Medicines Corp


  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $6.87B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track Virtus Fund Advisers, LLC Portfolio

Follow Virtus Fund Advisers, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus Fund Advisers, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus Fund Advisers, LLC with notifications on news.